Who owns AEGLEA BIOTHERAPEUTICS INC?
- Ticker: SYRE
- CUSIP Number: 00773j202
Tip: Access positions for across all investors
Analyze quarterly positions in Aeglea Biotherapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Aeglea Biotherapeutics stock
Who bought or sold AEGLEA BIOTHERAPEUTICS INC this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Perceptive Advisors | 2.6M | $56M | 3114% | Dec 2023 |
|
| VR Adviser | 2.4M | $51M | 100% | Dec 2023 |
|
| Commodore Capital | 1.9M | $41M | 1520% | Dec 2023 |
|
| venBio Select Advisor | 1.8M | $40M | 15951% | Dec 2023 |
|
| Cormorant Asset Management | 937k | $20M | 100% | Dec 2023 |
|
| EcoR1 Capital | 887k | $19M | 344% | Dec 2023 |
|
| Franklin Resources | 687k | $15M | 100% | Dec 2023 |
|
| BVF | 687k | $15M | 100% | Dec 2023 |
|
| Wellington Management Company | 636k | $14M | 112% | Dec 2023 |
|
| Citadel Advisors | 577k | $12M | 494% | Dec 2023 |
|
| Braidwell | 515k | $11M | 100% | Dec 2023 |
|
| Global Endowment Management | 513k | $11M | 100% | Dec 2023 |
|
| Fairmount Funds Management | 378k | $8.1M | 0% | Dec 2023 |
|
| Boxer Capital | 250k | $5.4M | 100% | Dec 2023 |
|
| Logos Global Management | 150k | $3.2M | -29% | Dec 2023 |
|
| Dr. Jeffrey R. Jay, M.D. | 125k | $2.7M | 100% | Dec 2023 |
|
| Millennium Management | 109k | $2.3M | 187% | Dec 2023 |
|
| Assenagon Asset Management | 64k | $2.4M | 100% | Mar 2024 |
|
| Barclays | 46k | $979k | 100% | Dec 2023 |
|
| Vanguard Group | 39k | $849k | 19% | Dec 2023 |
|
| Two Sigma Investments | 28k | $605k | 100% | Dec 2023 |
|
| Cubist Systematic Strategies | 26k | $563k | 100% | Dec 2023 |
|
| Marshall Wace | 20k | $436k | 100% | Dec 2023 |
|
| Blackstone Group | 20k | $430k | 100% | Dec 2023 |
|
| Legato Capital Management | 12k | $435k | 100% | Mar 2024 |
|
| Citigroup | 10k | $222k | 100% | Dec 2023 |
|
| Carlyle | 9.6k | $204k | 100% | Dec 2023 |
|
| ADAR1 Capital Management | 6.4k | $139k | 100% | Dec 2023 |
|
| Virtus ETF Advisers | 6.2k | $134k | 100% | Dec 2023 |
|
| Bank of New York Mellon | 6.1k | $230k | 100% | Mar 2024 |
|
| UBS Group | 3.7k | $80k | 100% | Dec 2023 |
|
| New York State Common Retirement Fund | 365.00 | $8.0k | 100% | Dec 2023 |
|
| Advisor Group Holdings | 283.00 | $6.1k | 0% | Dec 2023 |
|
| IFP Advisors | 114.00 | $2.5k | 0% | Dec 2023 |
|
| Jpmorgan Chase & Co | 41.00 | $882.000200 | 0% | Dec 2023 |
|
| Wells Fargo & Company | 23.00 | $494.999100 | 5% | Dec 2023 |
|
| Pacific Capital Wealth Advisors | 8.00 | $172.000000 | 100% | Dec 2023 |
|
| Parallel Advisors | 1.00 | $22.000000 | 100% | Dec 2023 |
|
Who sold out of Aeglea Biotherapeutics?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Aisling Capital Management | Sep 2023 | 68k | $829k |
| Royal Bank of Canada | Sep 2023 | 437.00 | $5.0k |